Effects of formulation design on niacin therapeutics: Mechanism of action, metabolism, and drug delivery

International Journal of Pharmaceutics

Volumn 490, Issue 1-2, 2015, Pages 55-64

  Cooper, Dustin L ^a   Murrell, Derek E ^a   Roane, David S ^a   Harirforoosh, Sam ^a  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Flushing; Formulation; Hepatotoxicity; Lipoprotein; Niacin; Nicotinic acid; Triglyceride

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NANOPARTICLE; NICOTINIC ACID; POLYMER; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; DELAYED RELEASE FORMULATION;

ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; FLUSHING; LIVER TOXICITY; PRIORITY JOURNAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DESIGN; DRUG EFFECTS; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NANOPARTICLES; NIACIN;

EID: 84930009781     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.024     Document Type: Review

References (94)

1. ®, 56th ed. American Society of Health-System Pharmacists, Bethesda, MD, 2015.
2. J.M. Backes, R.J. Padley, and P.M. Moriarty Important considerations for treatment with dietary supplement versus prescription niacin products Postgraduate Med. 123 2011 70 83
3. P. Barter HDL-C: role as a risk modifier Atherosclerosis Supplements 12 2011 267 270
4. M. Bassan A case for immediate-release niacin Heart Lung: J. Crit. Care 41 2012 95 98
5. H.E. Bays Extended-release niacin/lovastatin: the first combination product for dyslipidemia Expert Rev. Cardiovasc. Ther. 2 2004 485 501
6. H.E. Bays, C.A. Dujovne, M.E. McGovern, T.E. White, M.L. Kashyap, A.G. Hutcheson, J.R. Crouse, and A.D.V.O.C.-M.A.T. Evaluation Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor versus other cholesterol-modulating agents trial evaluation [ADVOCATE]) Am. J. Cardiol. 91 2003 667 672
7. L. Berglund, and R. Ramakrishnan Lipoprotein(a): an elusive cardiovascular risk factor Arterioscler Thromb. Vasc. Biol. 24 2004 2219 2226
8. J.S. Berns Niacin and related compounds for treating hyperphosphatemia in dialysis patients Semin. Dialysis 21 2008 203 205
9. S.S. Bhardwaj, and N. Chalasani Lipid-lowering agents that cause drug-induced hepatotoxicity Clin. Liver Dis. 11 2007 597 613 vii
10. R. Bitzur, H. Cohen, Y. Kamari, A. Shaish, and D. Harats Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 32 Suppl 2 2009 S373 377
11. G.K. Bolhuis, A.J. Smallenbroek, and C.F. Lerk Interaction of tablet disintegrants and magnesium stearate during mixing I: effect on tablet disintegration J. Pharma. Sci. 70 1981 1328 1330
12. J.D. Bos, and M.M. Meinardi The 500 Dalton rule for the skin penetration of chemical compounds and drugs Exp. Dermatol. 9 2000 165 169
13. B.G. Brown Can niacin slow the development of atherosclerosis in coronary artery disease patients already taking statins? Nature clinical practice Cardiovas. Med. 2 2005 234 235
14. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, R.J. Prineas, and W. Friedewald Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J. Am. Coll. Cardiol. 8 1986 1245 1255
15. L.A. Carlson Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug Int. J. Clin. Pract. 58 2004 706 713
16. L.A. Carlson, A. Hamsten, and A. Asplund Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid J. Intern. Med. 226 1989 271 276
17. F. Chen, D. Maccubbin, L. Yan, W. Sirah, E. Chen, C.M. Sisk, M. Davidson, P. Blomqvist, and J.M. McKenney Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia Int. J. Cardiol. 167 2013 225 231
18. I. Chennamsetty, K.M. Kostner, T. Claudel, M. Vinod, S. Frank, T.S. Weiss, M. Trauner, and G.M. Kostner Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice J. Lipid Res. 53 2012 2405 2412
19. M.C. Cheung, X.Q. Zhao, A. Chait, J.J. Albers, and B.G. Brown Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL Arterioscler. Thromb. Vasc. Biol. 21 2001 1320 1326
20. D.C. Chow, A. Tasaki, J. Ono, B. Shiramizu, and S.A. Souza Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome Biologics Targets Ther. 2 2008 917 921
21. M.C. Chuong, L. Palugan, T.M. Su, C. Busano, R. Lee, G. Di Pretoro, and A. Shah Formulation of controlled-release capsules of biopharmaceutical classification system I drugs using niacin as a model AAPS PharmSciTech. 11 2010 1650 1661
22. A.B. Clark, and J.M. Holt Identifying and managing patients with hyperlipidemia Am. J. Manage. Care 3 1997 1211 1219 quiz 1223-1215
23. W.H. De Jong, and P.J. Borm Drug delivery and nanoparticles:applications and hazards Int. J. Nanomed. 3 2008 133 149
24. Y. Ding, Y. Li, and A. Wen Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials Clinical nutrition. 2014 10.1016/j.clnu.2014.09.019 (in press)
25. M.A. Ellsworth, K.R. Anderson, D.J. Hall, D.K. Freese, and R.M. Lloyd Acute liver failure secondary to niacin toxicity Case Rep. Pediatr. 2014 2014 692530
26. Endurance Products Company, 2014. Endur-acin 500 mg. Endurance Products Company, Tigard, OR.
27. D.J. Fischer, L.L. Knight, and R.E. Vestal Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital West. J. Med. 155 1991 410 412
28. S.H. Ganji, V.S. Kamanna, and M.L. Kashyap Niacin and cholesterol: role in cardiovascular disease (review) J. Nutr. Biochem. 14 2003 298 305
29. S.H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V.S. Kamanna, and M.L. Kashyap Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells J. Lipid Res. 45 2004 1835 1845
30. E.K. Gupta, and M.K. Ito Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia Heart Dis. 4 2002 124 137
31. J.R. Guyton Extended-release niacin for modifying the lipoprotein profile Expert Opin. Pharmacother. 5 2004 1385 1398
32. J.R. Guyton, M.A. Blazing, J. Hagar, M.L. Kashyap, R.H. Knopp, J.M. McKenney, D.T. Nash, and S.D. Nash Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil StudyGroup Arch. Intern. Med. 160 2000 1177 1184
33. Guyton, J.R., Capuzzi, D.M., 1998. Treatment of hyperlipidemia with combined niacin-statin regimens. The American journal of cardiology 82, 82U-84U; discussion 85-86U.
34. HPS THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur. Heart J. 34 2013 1279 1291
35. HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N. Engl. J. Med. 371 2014 203 212
36. M.K. Ito Niacin-based therapy for dyslipidemia: past evidence and future advances Am. J. Manage. Care 8 2002 S315 322
37. E.L. Jacobson, H. Kim, M. Kim, J.D. Williams, D.L. Coyle, W.R. Coyle, G. Grove, R.L. Rizer, M.S. Stratton, and M.K. Jacobson A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin Exp. Dermatol. 16 2007 490 499
38. T.A. Jacobson A hot topic in dyslipidemia management-how to beat a flush: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention Mayo Clin. Proc. 85 2010 365 379
39. S. Kamal-Bahl, D.J. Watson, and B.M. Ambegaonkar Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview Clin. Ther. 31 2009 130 140
40. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap The mechanism and mitigation of niacin-induced flushing Int. J. Clin. Prac. 63 2009 1369 1377
41. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin Am. J. Cardiol. 101 2008 20B 26B
42. J.M. Keenan, P.L. Fontaine, J.B. Wenz, S. Myers, Z.Q. Huang, and C.M. Ripsin Niacin revisited. A randomized: controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia Arch. Intern. Med. 151 1991 1424 1432
43. T.Z. Khan, A. Pottle, D.J. Pennell, and M.S. Barbir The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina Global Cardiol. Sci. Prac. 2014 2014 3 12
44. R.H. Knopp Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing Am. J. Cardiol. 82 1998 24U 28U discussion 39U-41U
45. R.H. Knopp Evaluating niacin in its various forms Am. J. Cardiol. 86 2000 51L 56L
46. A. Kumari, S.K. Yadav, and S.C. Yadav Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf. B 75 2010 1 18
47. X. Li, J.S. Millar, N. Brownell, F. Briand, and D.J. Rader Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes Biochem. Pharmacol. 80 2010 1450 1457
48. A. Linke, M. Sonnabend, M. Fasshauer, R. Hollriegel, G. Schuler, J. Niebauer, M. Stumvoll, and M. Bluher Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance Atherosclerosis 205 2009 207 213
49. K.A. Lyseng-Williamson Niacin extended release (ER)/simvastatin (Simcor(R)): a guide to its use in lipid regulation Drugs R&D 10 2010 253 260
50. D. Maccubbin, H.E. Bays, A.G. Olsson, V. Elinoff, A. Elis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, Q. Yu, O. Kuznetsova, C.M. Sisk, R.C. Pasternak, and J.F. Paolini Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int. J. Clin. Prac. 62 2008 1959 1970
51. D. Maccubbin, M.J. Koren, M. Davidson, D. Gavish, R.C. Pasternak, G. Macdonell, M. Mallick, C.M. Sisk, J.F. Paolini, and Y. Mitchel Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease Am. J. Cardiol. 104 2009 74 81
52. D.L. Maccubbin, F. Chen, J.W. Anderson, W. Sirah, C. McCrary Sisk, U. Kher, A.G. Olsson, H.E. Bays, and Y.B. Mitchel Effectiveness and safety of laropiprant on niacin-induced flushing Am. J. Cardiol. 110 2012 817 822
53. D. MacKay, J. Hathcock, and E. Guarneri Niacin: chemical forms, bioavailability, and health effects Nutr. Rev. 70 2012 357 366
54. V. Maravajhala, N. Dasari, A. Sepuri, and S. Joginapalli Design and evaluation of niacin microspheres Indian J. Pharm. Sci. 71 2009 663 669
55. E. Marin, M.I. Briceno, and C. Caballero-George Critical evaluation of biodegradable polymers used in nanodrugs Int. J. Nanomed. 8 2013 3071 3090
56. L. Masana, A. Cabre, and N. Plana HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe? Atherosclerosis 229 2013 449 450
57. P.L. McCormack, and G.M. Keating Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia Drugs 65 2005 2719 2740
58. J. McKenney Niacin for dyslipidemia: considerations in product selection Am. J. Health-Syst. Pharm. AJHP: Off. J. Am. Soc. Health-Syst. Pharm. 60 2003 995 1005
59. J. McKenney New perspectives on the use of niacin in the treatment of lipid disorders Arch. Intern. Med. 164 2004 697 705
60. O.N. Miller, J.G. Hamilton, and G.A. Goldsmith On the mechanism of action of nicotinic acid in lowering serum lipids The American journal of clinical nutrition 10 1962 285 296
61. Y.S. Moon, and M.L. Kashyap Niacin extended-release/lovastatin: combination therapy for lipid disorders Expert Opin. Pharmacother. 3 2002 1763 1771
62. A. Moore, B.A. Phan, C. Challender, J. Williamson, S. Marcovina, and X.Q. Zhao Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease J. Clin. Lipidol. 1 2007 620 625
63. A. Noma, S. Maeda, M. Okuno, A. Abe, and Y. Muto Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate Atherosclerosis 84 1990 213 217
64. A. Pandian, A. Arora, L.S. Sperling, and B.V. Khan Targeting multiple dyslipidemias with fixed combinations-focus on extended release niacin and simvastatin Vasc. Health Risk Manage. 4 2008 1001 1009
65. J.F. Paolini, Y.B. Mitchel, R. Reyes, U. Kher, E. Lai, D.J. Watson, J.M. Norquist, A.G. Meehan, H.E. Bays, M. Davidson, and C.M. Ballantyne Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am. J. Cardiol. 101 2008 625 630
66. K.S. Paudel, M. Milewski, C.L. Swadley, N.K. Brogden, P. Ghosh, and A.L. Stinchcomb Challenges and opportunities in dermal/transdermal delivery Ther. Deliv. 1 2010 109 131
67. C.M. Perry Extended-release niacin (nicotinic acid)/laropiprant Drugs 69 2009 1665 1679
68. J.A. Pieper Understanding niacin formulations Am. J. Manage. Care 8 2002 S308 314
69. J.A. Pieper Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety Am. J. Health-Syst. Phar. AJHP: Off. J. Am. Soc. Health-Syst. Pharm. 60 2003 S9 S14 quiz S25
70. R.W. Piepho The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol Am. J. Cardiol. 86 2000 35L 40L
71. N.B. Pike Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid J. Clin. Invest. 115 2005 3400 3403
72. M.R. Prausnitz, and R. Langer Transdermal drug delivery Nat. Biotechnol. 26 2008 1261 1268
73. N.M. Price, L.G. Schmitt, J. McGuire, J.E. Shaw, and G. Trobough Transdermal scopolamine in the prevention of motion sickness at sea Clin. Pharmacol. Ther. 29 1981 414 419
74. T. Rhodes, J.M. Norquist, C.M. Sisk, K. McQuarrie, A. Trovato, J. Liao, T. Miller, D. Maccubbin, and D.J. Watson The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy Int. J. Clin. Prac. 67 2013 1238 1246
75. N. Ruparelia, J.E. Digby, and R.P. Choudhury Effects of niacin on atherosclerosis and vascular function Curr. Opin. Cardiol. 26 2011 66 70
76. RxList, 2014. Advicor drug. WebMD, New York.
77. RxList, 2014. Niacor drug. WebMD, New York.
78. RxList, 2014. Niaspan drug. WebMD, New York.
79. RxList, 2014. Simcor drug. WebMD, New York.
80. T. Sakai, V.S. Kamanna, and M.L. Kashyap Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol Arterioscler. Thromb. Vasc. Biol. 21 2001 1783 1789
81. S. Sanyal, R.H. Karas, and J.T. Kuvin Present-day uses of niacin: effects on lipid and non-lipid parameters Expert Opin. Pharmacother. 8 2007 1711 1717
82. N.H. Shah, J.H. Lazarus, P.R. Sheth, and C.I. Jarowski Carboxymethylcellulose: effect of degree of polymerization and substitution on tablet disintegration and dissolution J. Pharm. Sci. 70 1981 611 613
83. S. Shah, R. Ceska, B. Gil-Extremera, J.F. Paolini, H. Giezek, K. Vandormael, A. Mao, C. McCrary Sisk, and D. Maccubbin Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int. J. Clin. Prac. 64 2010 727 738
84. A. Sharma, A. Khatchadourian, K. Khanna, R. Sharma, A. Kakkar, and D. Maysinger Multivalent niacin nanoconjugates for delivery to cytoplasmic lipid droplets Biomaterials 32 2011 1419 1429
85. K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, and W.E. Rudzinski Biodegradable polymeric nanoparticles as drug delivery devices J. Controlled Release Off. J. Controlled Release Soc. 70 2001 1 20
86. B.M. Tashtoush, A.N. Bennamani, and B.M. Al-Taani Preparation and characterization of microemulsion formulations of nicotinic acid and its prodrugs for transdermal delivery Pharm. Dev. Technol. 18 2013 834 843
87. The Coronary Drug Project Research Group The Coronary Drug Project Research Group, Clofibrate and niacin in coronary heart disease Jama 231 1975 360 381
88. T.C. Villines, A.S. Kim, R.S. Gore, and A.J. Taylor Niacin: the evidence, clinical use, and future directions Curr. Atheroscler. Rep. 14 2012 49 59
89. H. Vosper Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters Clin. Med. Insights. Cardiol. 5 2011 85 101
90. X. Xu, W.C. Yee, P.Y. Hwang, H. Yu, A.C. Wan, S. Gao, K.L. Boon, H.Q. Mao, K.W. Leong, and S. Wang Peripheral nerve regeneration with sustained release of poly(phosphoester) microencapsulated nerve growth factor within nerve guide conduits Biomaterials 24 2003 2405 2412
91. X. Xu, H. Yu, S. Gao, H.Q. Ma, K.W. Leong, and S. Wang Polyphosphoester microspheres for sustained release of biologically active nerve growth factor Biomaterials 23 2002 3765 3772
92. R. Yadav, M. France, N. Younis, S. Hama, B.J. Ammori, S. Kwok, and H. Soran Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety Expert Opin. Pharmacother. 13 2012 1345 1362
93. B.T. Yim, and P.H. Chong Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia Ann. Pharmacother. 37 2003 106 115
94. A. Zambon, X.Q. Zhao, B.G. Brown, and J.D. Brunzell Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease Am. J. Cardiol. 113 2014 1494 1498